Resistance factors and proliferative activity in childhood acute nonlymphoblastic leukemia

Area of Science:

• Pediatric Oncology
• Molecular Biology
• Cancer Research

Background:

• Acute nonlymphoblastic leukemia (ANLL) in children presents a significant challenge in achieving long-term remission.
• Understanding the molecular mechanisms, including drug resistance markers and proliferation indices, is crucial for improving treatment outcomes.

Purpose of the Study:

• To investigate the expression of P-glycoprotein (P-170), glutathione S-transferase-pi (GST-pi), topoisomerase II (Topo II), and the proliferation antigen Ki-67 in pediatric ANLL.
• To correlate the expression of these markers with treatment response, specifically remission rates.

Main Methods:

• Analysis of 34 children with newly diagnosed ANLL using the streptavidin-biotin-peroxidase method.
• Quantification of P-170, GST-pi, Topo II, and Ki-67 expression.
• Statistical analysis to correlate marker expression with remission rates and clinical parameters.

Main Results:

• Overexpression of P-170 (76%) and GST-pi (32%) was common.
• Downregulation of Topo II (47%) and low Ki-67 expression (26%) were observed in a significant proportion of patients.
• Lower remission rates were associated with Topo II downregulation and low Ki-67 expression. P-170 expression showed a non-significant trend towards lower remission probability.

Conclusions:

• Topo II downregulation and low proliferative activity (Ki-67) are associated with poorer remission in pediatric ANLL.
• While P-170 and GST-pi overexpression were frequent, their direct impact on remission rates was not statistically significant in this cohort.
• These findings suggest potential prognostic value for Topo II and Ki-67 in pediatric ANLL, independent of clinical parameters.